Related Experiment Video
Updated: Jul 14, 2026
05:31
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma
S Herber1, G Otto, J Schneider
1Department of Diagnostic and Interventional Radiology, University of Mainz, Langenbeckstr. 1, 55131 Mainz, Germany. herber@radiologie.klinik.uni-mainz.de
Cardiovascular and Interventional Radiology
|May 18, 2007
Summary
Chemoembolization (TACE) offers a safe palliative option for unresectable intrahepatic cholangiocarcinoma (CCA), showing potential to prolong survival compared to intravenous chemotherapy. This study found TACE to be generally well-tolerated with manageable complications in CCA patients.
Area of Science:
- Interventional Radiology
- Hepatobiliary Oncology
- Medical Oncology
Background:
- Intrahepatic cholangiocarcinoma (CCA) is a challenging liver cancer.
- Unresectable CCA often requires palliative treatment to improve outcomes.
- Transarterial chemoembolization (TACE) is an option for locoregional tumor control.
Purpose of the Study:
- To evaluate the safety and efficacy of TACE for unresectable intrahepatic CCA.
- To compare TACE outcomes with existing literature on palliative treatments for CCA.
- To assess survival rates and complications associated with TACE in CCA patients.
Main Methods:
- Retrospective analysis of 15 patients with unresectable CCA treated with TACE.
- TACE involved injecting Lipiodol and mitomycin C into tumor-supplying vessels.
- Treatment included repeated TACE sessions at 8-week intervals, with follow-up CT scans and lab tests.
Main Results:
- Mean survival was 21.1 months, with 1-, 2-, and 3-year survival rates of 51.3%, 27.5%, and 27.5% respectively.
- Best response was stable disease in 9/15 patients; 1 partial response and 4 progressions were noted.
- TACE was safe, with no deaths or acute liver failure; two major complications (anaphylactic shock, gastric ulceration) occurred.
Conclusions:
- TACE is a safe palliative treatment for inoperable intrahepatic cholangiocarcinoma.
- The procedure is associated with a moderate complication rate.
- TACE may prolong survival in selected CCA patients compared to intravenous chemotherapy.
